Activity and Safety of Second Line SOrafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study)
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary) ; Pazopanib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SOAP; TOKIO
- 25 Aug 2017 Planned End Date changed from 1 May 2016 to 1 May 2018.
- 25 Aug 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2017.
- 20 Jun 2015 Status changed from not yet recruiting to recruiting according to trial design published in the Tumori.